John Theurer Cancer Center Opens New Comprehensive Facility

Publication
Article
Oncology Nursing NewsDecember 2010
Volume 4
Issue 6

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States, recently opened a new $130-million, 155,000-square-foot comprehensive cancer facility. “This new facility will help us build on our promise to deliver extraordinary care by providing patients with an unparalleled experience through innovative approaches in comfortable surroundings,” said Andrew L. Pecora, MD, FACP, CPE, chief innovations officer and professor and vice president of cancer services, JTCC.

Articles in this issue
Net Guides: Melanoma
Net Guides: Bone Metastases
Yoga for Cancer Care
FDA Updates
The Future of Nursing
Net Guides: Liver Cancer
Net Guides: Carcinoma of Unknown Primary Orgin
Tools to Help Patients Navigate Their Treatment Path
John Theurer Cancer Center Opens New Comprehensive Facility
Bone Loss Drugs Increase Stroke Risk in Patients With Cancer
Oncology Community Facing Severe Drug Shortages
Net Guides: Oral Cancer

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Image of a woman with gray hair on a light blue background
Photo of a man wearing scrubs in front of a blue background
a man wearing a suit and tie in front of a green screen with the ONN logo
Elizabeth Burton in an interview with Oncology Nursing News
A panel of 3 experts on CML
Related Content
Photo of an APP talking to and empowering a patient

Case Study: Bridging the Gap for Patients With Metastatic CRC

Randi Kihnel, MSN, APRN, ACCNS-AG
June 13th 2025
Article

Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Graphic that resembles a stamp of approval reading "FDA Approved"

Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer

Bridget Hoyt
June 11th 2025
Article

The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Anatomical graphic of a person with a tumor in their left lung

Tarlatamab Supported as Second-Line SOC by DeLLphi-304 in SCLC

Chris Ryan
June 4th 2025
Article

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.

Photo of a person in a lab coat inspecting the arm of a woman

Dermatologic Protocol Preserves QOL in EGFR+ Advanced NSCLC Treatment

Russ Conroy
June 4th 2025
Article

COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC.